investigator_user
investigator
user
funding
collaborators
pending
menu
bell
message
arrow_up
arrow_down
filter
layers
globe
marker
add
arrow
close
download
edit
facebook
info
linkedin
minus
plus
save
share
search
sort
twitter
remove
user-plus
user-minus
Sign Up for Updates
Map
Countries
Cancer types
All cancers but non-melanoma skin cancer
Bladder
Brain, nervous system
Breast
Cervix uteri
Colorectum
Corpus uteri
Gallbladder
Hodgkin lymphoma
Kaposi sarcoma
Kidney, renal pelvis and ureter
Larynx
Leukaemia
Lip, oral cavity
Liver and intrahepatic bile ducts
Melanoma of skin
Multiple myeloma and immunoproliferative diseases
Nasopharynx
Non-Hodgkin lymphoma
Non-Melanoma skin cancer
Oesophagus
Other pharynx
Ovary
Pancreas
Prostate
Sarcoma
Stomach
Testis
Thymus
Thyroid
Trachea, bronchus and lung
Specialities
Hematology and hematologic malignancies
Palliative Care
Pathology
Pediatric oncology or childhood cancer
Radiation Oncology
Surgery / Surgical oncology
Blog
About
Login
Project leads
Collaborators
Elucidating the functions of Bud31, an essential gene in Myc-driven breast cancer
Tiffany Y Hsu
0 Collaborator(s)
Funding source
National Institutes of Health (NIH)
Follow
+ Project
+ Post
+ Event
Info
People
Posts
Tiffany Y Hsu
Baylor College of Medicine
Houston, United States
Related projects
Targeted Epigenetic Therapy of Triple-Negative Breast Cancer
Breast
Yuet Ming Rebecca Chin
Akt isoform-specific signaling in breast cancer metastasis
Breast
Fariba Behbod
Elucidating Cellular Heterogeneity Among Cancer Stem Cells by Raman Spectroscopy
Breast
Radiation Oncology
Zhihong Gong
Aberrant DNA methylation patterns of miRNAs and breast cancer racial disparities
Breast
Donald W. Kufe
Oncogenic Signaling by DF3/MUC1 in Human Breast Cancer
Breast
Li Tang
Nutrigenetics of cruciferous vegetable intake and breast cancer prognosis
Breast
Thomas Ried
Identifying Diagnostic Markers for Cervical, Breast, and Prostate Cancer
Breast
Needs Assessment to Assess Barriers to Developing a Comprehensive Cancer Center in LMICs
Breast
Nathanael S Gray
Developing Selective EphA2 Inhibitors for the Treatment of Cancer
Breast